ESC Professional Premium Access

Coronary artery disease - Pharmacotherapy 1

Event: ESC Congress 2022
Topic: Pharmacotherapy
Session type: Moderated ePosters
Date: 27 August 2022
Time: 13:15 - 13:40

Congress Session

5 presentations in this session

Sodium-glucose co-transporter-2 inhibitors after acute myocardial infarction in type 2 diabetes patients: a population-based investigation from South Korea

Speaker: Doctor O. Kwon (Seoul, KR)
Thumbnail

Activation of mitochondrial telomerase reverses relative lymphopenia post myocardial infarction: results from the randomised, double-blinded TACTIC phase IIa pilot trial

Speaker: Professor I. Spyridopoulos (Newcastle-Upon-Tyne, GB)
Thumbnail

Blood pressure and clinical outcomes in patients with diabetes and stable coronary artery disease in THEMIS

Speaker: Doctor M. Pareek (Copenhagen, DK)
Thumbnail

Effect of rivaroxaban monotherapy vs. combination with anti-platelet therapy in patients with atrial fibrillation and stable coronary artery disease across different body mass index categories

Speaker: Doctor M. Ishii (Nobeoka, JP)
Thumbnail

Direct cost analysis of genetic testing for CYP2C19*2 and *3 loss of function variants in percutaneous coronary intervention patients

Speaker: Doctor S. Huxley (Rochester, US)
Thumbnail

5 speakers from this session

Doctor Osung Kwon

Eunpyeong St. Mary's Hospital, Seoul (Korea (Republic of))
0 follower

Professor Ioakim Spyridopoulos

Newcastle University, Newcastle-Upon-Tyne (United Kingdom of Great Britain & Northern Ireland)
0 follower

Doctor Manan Pareek

Herlev and Gentofte Hospital, Copenhagen (Denmark)
1 presentation
0 follower

Doctor Masanobu Ishii

Nobeoka Hospital, Nobeoka (Japan)
0 follower

Doctor Samuel Huxley

Mayo Clinic Hospital-Rochester, Rochester (United States of America)
0 follower

This platform is supported by

logo Novo Nordisk